MaxCyte, Inc.
US ˙ NasdaqGS ˙ US57777K1060

SecurityMXCT / MaxCyte, Inc.
InstitutionLazard Asset Management Llc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Lazard Asset Management Llc closes position in MXCT / MaxCyte, Inc.

On November 14, 2025 - Lazard Asset Management Llc filed a 13F-HR form disclosing ownership of 0 shares of MaxCyte, Inc. (US:MXCT) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 284,498 shares of MaxCyte, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F MAXCYTE Common Stock 57777K106 0 -284,498 -100.00 0 0.0000
2025-08-14 2025-06-30 13F MAXCYTE Common Stock 57777K106 284,498 137,983 94.18 1 0.0009
2025-05-15 2025-03-31 13F MAXCYTE Common Stock 57777K106 146,515 -16,980 -10.39 0 0.0006
2025-02-14 2024-12-31 13F MAXCYTE Common Stock 57777K106 163,495 -197,955 -54.77 1 -100.00 0.0010
2024-11-14 2024-09-30 13F MAXCYTE Common Stock 57777K106 361,450 -51,448 -12.46 1 0.00 0.0019
2024-08-14 2024-06-30 13F MAXCYTE Common Stock 57777K106 412,898 -54,789 -11.71 2 0.00 0.0020
2024-07-09 2024-03-31 13F/A-1 MAXCYTE Common Stock 57777K106 467,687 100,555 27.39 2 0.00 0.0024
2024-05-14 2024-03-31 13F MAXCYTE Common Stock 57777K106 467,687 100,555 2 0.0024
2024-02-14 2023-12-31 13F MAXCYTE Common Stock 57777K106 367,132 -90,236 -19.73 2 0.00 0.0022
2023-11-14 2023-09-30 13F MAXCYTE Common Stock 57777K106 457,368 -13,084 -2.78 1 -50.00 0.0019
2023-08-15 2023-06-30 13F MAXCYTE Common Stock 57777K106 470,452 3,322 0.71 2 0.00 0.0027
2023-05-15 2023-03-31 13F MAXCYTE Common Stock 57777K106 467,130 110,069 30.83 2 -99.90 0.0030
2023-02-15 2022-12-31 13F MAXCYTE Common Stock 57777K106 357,061 -128,043 -26.39 1,949 -38.19 0.0027
2022-11-14 2022-09-30 13F MAXCYTE Common Stock 57777K106 485,104 18,503 3.97 3,153 42.86 0.0046
2022-08-09 2022-06-30 13F MAXCYTE Common Stock 57777K106 466,601 466,601 2,207 0.0030
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.